News & Views - Page 13 of 52 - Telix Pharmaceuticals Limited

Illuccix® Approved in the United Kingdom

Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).

Illuccix® Approved in Denmark

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved by the Danish Medicines Agency (Lægemiddelstyrelsen).

Telix Full Year Results 2024 Investor Webcast Notification

Telix today advises that it will release its full year results and Australian Annual Report for the period ended 31 December 2024 on Thursday 20 February 2025. 

Statement on impact of U.S. tariffs

Telix currently generates most of its revenue from U.S. sales of Illuccix®. Because of the “just-in-time” nature of radiopharmaceutical products, such products are generally manufactured in close proximity to the customer. This will continue to be the case for new products that are anticipated to be launched in 2025.

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Telix today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities.

Telix Completes Acquisition of RLS (USA) Inc.

Telix today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals.

Illuccix® Receives European Approval

Telix today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP).

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.).

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Telix today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).

Scintimun® Commercialization Partnership with Curium Pharma

Telix today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic radiopharmaceutical used for infection imaging. The agreement also includes a strategic contract manufacturing agreement appointing Curium as the manufacturer of the product for Telix.